Literature DB >> 16680129

Gold in the ivory tower: equity rewards of outlicensing.

Mark Edwards1, Fiona Murray, Robert Yu.   

Abstract

An analysis of life-science initial public offerings from three time periods reveals that the equity share received by universities and their academic researchers has changed over time.

Mesh:

Year:  2006        PMID: 16680129     DOI: 10.1038/nbt0506-509

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  1 in total

1.  Translational science by public biotechnology companies in the IPO "class of 2000": the impact of technological maturity.

Authors:  Laura McNamee; Fred Ledley
Journal:  PLoS One       Date:  2013-12-16       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.